author-photo

Mark Grose

Merck & Co.

24

Papers

224

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
381 Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT114: The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (15)
Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (20)
Abstract CT115: Phase 1b KEYNOTE 200 (STORM study): A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (6)
Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (15)
Intravenous coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients: phase Ib KEYNOTE 200 study

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Abstract CT021: Phase Ib study of a novel immunotherapy combination therapy of intralesional coxsackievirus A21 and systemic ipilimumab in patients with advanced melanoma

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Abstract CT053: Intratumoral coxsackievirus A21 increases immune-cell infiltrates and upregulates immune-checkpoint molecules in the tumor microenvironment of advanced melanoma patients: phase II CALM extension study

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)